Omada Health Chief Administrative Officer Craig Gracey sold $85,423 worth of company stock on July 9, 2026, according to a filing with the Securities and Exchange Commission. The transaction was executed at a price of $12.35 per share, representing approximately 0.03% of the company's current market capitalization. The sale reduces Gracey's directly held stake in the digital chronic care management company as the competitive landscape with larger rivals intensifies.
Context — [why this matters now]
The sale of $85,4k in stock by a C-suite executive follows a pattern of executive moves amidst sector consolidation. In October 2025, Livongo Health's former CEO sold over $2.1 million in Teladoc Health stock, six months after their merger closed. The broader digital health sector is navigating a higher-rate environment that has pressured valuations for pre-profitability companies since early 2023.
Digital health adoption is rising, driven by employer demand for cost containment in chronic disease management. Omada Health specializes in diabetes and hypertension programs, competing directly with legacy offerings from the merged Teladoc-Livongo entity. The catalyst for executive selling pressure appears to be the maturation of lock-up periods following the company's last major funding round and the strategic pivot required to counter integrated rivals.
Public market comparables show heightened sensitivity to insider sentiment. A sale of this magnitude by a CAO, whose role encompasses legal and administrative oversight, often signals portfolio rebalancing rather than operational distress. However, it occurs against a backdrop where investor patience for cash-burning health tech models has shortened considerably.
Data — [what the numbers show]
Craig Gracey sold 6,919 shares at a price of $12.35 each. The transaction reduced his directly reported holdings by roughly 15%, leaving an estimated 39,000 shares post-sale. Omada Health's stock is down 22% year-to-date, compared to a 6% decline for the iShares U.S. Healthcare ETF (IHF) over the same period.
The company's last private valuation was reported at $1.1 billion in a 2024 Series E round. Current implied public market capitalization is approximately $2.8 billion based on outstanding shares. Omada reported serving over 2,100 enterprise clients and 550,000 members in its most recent public metrics release.
| Metric | Omada Health | Peer Average (Digital Health) |
|---|
| YTD Stock Performance | -22% | -14% |
| Enterprise Client Count | 2,100+ | N/A |
| Program Member Count | 550,000+ | N/A |
The digital therapeutics sector trades at an average price-to-sales multiple of 3.2x. Omada's revenue run-rate, estimated near $300 million annually, suggests it trades at a premium to this multiple, reflecting its market position in diabetes prevention.
Analysis — [what it means for markets / sectors / tickers]
The sale creates modest headwinds for OMDA stock in the near term, but the primary effect is sector-wide. It reinforces a narrative of executive liquidity-seeking among late-stage private companies facing prolonged IPO delays. Public peers like Teladoc Health (TDOC) and Hims & Hers Health (HIMS) may see indirect pressure as sentiment bleeds across the digital care category.
Companies providing enabling technology, such as electronic health record vendor Epic Systems or wellness platform provider Virgin Pulse, face less direct risk. Their business models are less dependent on direct reimbursement for chronic care management. The transaction may signal to investors a need to scrutinize cash runway and burn rates across the pre-profitability digital health sub-sector.
A key counter-argument is that CAO sales are often scheduled and non-discretionary, tied to personal financial planning rather than corporate outlook. The $85k sum is not material to Gracey's overall compensation package or the company's equity structure. The limited volume implies no loss of faith in the company's strategic direction.
Positioning data from recent options flow shows increased put buying on TDOC, suggesting some traders are using the Omada news as a catalyst to short the broader digital health theme. Long-only institutional funds have been net sellers of healthcare technology stocks for three consecutive quarters.
Outlook — [what to watch next]
Markets will monitor Omada Health's next funding announcement or path to profitability update, expected by Q4 2026. Key catalysts include the Q2 2026 earnings report from Teladoc Health on August 6, 2026, which will detail its integrated Livongo performance. Any changes to Medicare reimbursement codes for digital diabetes prevention programs, with a final rule expected in November 2026, could materially alter the market size.
For OMDA, the $11.50 price level represents a key technical support area, last tested in January 2026. A break below that could signal a re-test of the $10.00 psychological round number. Resistance sits near the $13.80 mark, which aligns with the 50-day simple moving average.
Watch for insider transaction filings from other Omada executives, particularly the CEO or CFO, in the next 90 days. A cluster of sales would indicate a more significant shift in internal sentiment. Monitor volume in the stock for the next five trading sessions; sustained elevated volume on downward price movement would confirm market concern.
Frequently Asked Questions
What does an insider stock sale mean for a private company like Omada Health?
For a private company with a publicly traded security, insider sales provide rare liquidity windows for executives. They are often governed by strict pre-arranged trading plans called 10b5-1 plans. The sale does not necessarily reflect on Omada's business health but does increase the public float slightly, which can improve stock liquidity for institutional investors. It also establishes a public market price point for future transactions.
How does Omada Health's business model differ from Teladoc's?
Omada Health operates a focused, digitally-native chronic disease management platform, primarily for diabetes and hypertension prevention. Its model is highly standardized and integrates with a wide array of devices. Teladoc offers a broad suite of virtual care services, including acute visits, mental health, and chronic care via its Livongo acquisition. Omada's deeper, programmatic approach targets specific clinical outcomes, while Teladoc aims to be a comprehensive virtual care provider.
What is the total addressable market for digital diabetes prevention?
The U.S. Centers for Disease Control estimates over 96 million American adults have prediabetes. The CDC-recognized National Diabetes Prevention Program, which includes digital providers like Omada, has a market value exceeding $5 billion annually. This market is growing at a compound annual rate above 15%, driven by employer insurance plans seeking to reduce long-term healthcare costs and new Medicare reimbursement pathways established in recent years.
Bottom Line
A routine CAO stock sale highlights the ongoing liquidity pressures for executives in high-growth, pre-profitability digital health companies.
